12:00 AM
 | 
Feb 04, 2013
 |  BC Week In Review  |  Clinical News  |  Regulatory

Gleevec imatinib regulatory update

FDA approved an sNDA for Gleevec imatinib from Novartis to treat pediatric patients with newly diagnosed Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL) in combination with chemotherapy. The BCR-ABL tyrosine kinase...

Read the full 141 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >